S&P Futures
4,273.75 -12.75 (-0.30%) Dow Futures
33,914.00 -67.00 (-0.20%) Nasdaq Futures
13,475.00 -48.25 (-0.36%) Russell 2000 Futures
1,992.40 -9.30 (-0.46%) Crude Oil
89.82 -0.68 (-0.75%) Gold
1,768.10 -3.10 (-0.18%)
Awakn Life Sciences Corp. (AWKN.NE)
Chart Events
Performance Outlook
| Previous Close | 0.6500 |
| Open | 0.6500 |
| Bid | 0.6800 x N/A |
| Ask | 0.7200 x N/A |
| Day's Range | 0.6300 - 0.7300 |
| 52 Week Range | 0.4500 - 3.3500 |
| Volume | |
| Avg. Volume | 23,264 |
| Market Cap | 19.381M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7250 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AWKN.NE
Related Research
- Newsfile
Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada
Licensing Partnership with Wellbeings(R) marks entry into Canadian addiction treatment and relapse prevention market Toronto, Ontario--(Newsfile Corp. - August 18, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has signed its first licensing partnership agreement in Cana
- Business Wire
Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space
VANCOUVER, British Columbia, August 15, 2022--REVITALIST LIFESTYLE AND WELLNESS LTD. ("Revitalist" or the "Company") (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) announces it has signed a licensing partnership agreement with Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’) to implement their KARE® protocol for those suffering from Alcohol Use Disorder seeking sustained recovery measures focused on relapse prevention.
- Newsfile
Awakn Life Sciences Expands Commercial Operations into the U.S. - First Licensing Partnership Agreement with Revitalist
Awakn enters the U.S. addiction treatment and relapse prevention market Toronto, Ontario--(Newsfile Corp. - August 15, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), announces today it has signed a licensing partnership agreement with Revitalist Lifestyle and Wellness Ltd. (CSE: CALM) (OTC
